|
1
|
Petroski MD and Deshaies RJ: Function and
regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol.
6:9–20. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burnatowska-Hledin MA, Kossoris JB, Van
Dort CJ, Shearer RL, Zhao P, Murrey DA, Abbott JL, Kan CE and
Barney CC: T47D breast cancer cell growth is inhibited by
expression of VACM-1, a cul-5 gene. Biochem Biophys Res Commun.
319:817–825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnson AE, Le IP, Buchwalter A and
Burnatowska-Hledin MA: Estrogen-dependent growth and estrogen
receptor (ER)-alpha concentration in T47D breast cancer cells are
inhibited by VACM-1, a cul 5 gene. Mol Cell Biochem. 301:13–20.
2007. View Article : Google Scholar
|
|
4
|
Xu XM, Wang XB, Chen MM, Liu T, Li YX, Jia
WH, Liu M, Li X and Tang H: MicroRNA-19a and -19b regulate cervical
carcinoma cell proliferation and invasion by targeting CUL5. Cancer
Lett. 322:148–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma C, Qi Y, Shao L, Liu M, Li X and Tang
H: Downregulation of miR-7 upregulates cullin 5 (CUL5) to
facilitate G1/S transition in human hepatocellular carcinoma cells.
IUBMB Life. 65:1026–1034. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
American Cancer Society Cancer facts &
figures 2014. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-041770.pdf.
Accessed February 10, 2014.
|
|
7
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2010. National Cancer
Institute; Bethesda, MD, USA: http://seer.cancer.gov/csr/1975_2011/,
based on November 2013 SEER data submission, posted to the SEER
website, April 2014.
|
|
8
|
Devor EJ, Hovey AM, Goodheart MJ,
Ramachandran S and Leslie KK: microRNA expression profiling of
endometrial endometrioid adenocarcinomas and serous adenocarcinomas
reveals profiles containing shared, unique and differentiating
groups of microRNAs. Oncol Rep. 26:995–1002. 2011.PubMed/NCBI
|
|
9
|
Rapti SM, Kontos CK, Papadopoulos IN and
Scorilas A: Enhanced miR-182 transcription is a predictor of poor
overall survival in colorectal adenocarcinoma patients. Clin Chem
Lab Med. 52:1217–1227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Albitar L, Pickett G, Morgan M, Davies S
and Leslie KK: Models representing type I and type II human
endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol.
106:52–64. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
12
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative Ct method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar
|
|
13
|
Snedecor GW and Cochran WG: Statistical
Methods. 8th edition. Iowa State University Press; Ames, IA: pp.
158–160. 1989
|
|
14
|
Stanic B, Katsuyama M and Miller FJ Jr: An
oxidized extracellular oxidation-reduction state increases Nox1
expression and proliferation in vascular smooth muscle cells via
epidermal growth factor receptor activation. Arterioscler Thromb
Vasc Biol. 30:2234–2241. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li LC and Dahiya R: MethPrimer: Designing
primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hashimoto Y, Akiyama Y, Otsubo T, Shimada
S and Yuasa Y: Involvement of epigenetically silenced microRNA-181c
in gastric carcinogenesis. Carcinogenesis. 31:777–784. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Burnatowska-Hledin M and Barney CC: New
insights into the mechanism for VACM-1/cul5 expression in vascular
tissue in vivo. Int Rev Cell Mol Biol. 313:79–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Burnatowska-Hledin M, Zhao P, Capps B,
Poel A, Parmelee K, Mungall C, Sharangpani A and Listenberger L:
VACM-1, a cullin gene family member, regulates cellular signaling.
Am J Physiol Cell Physiol. 279:C266–C273. 2000.PubMed/NCBI
|
|
19
|
Van Dort C, Zhao P, Parmelee K, Capps B,
Poel A, Listenberger L, Kossoris J, Wasilevich B, Murrey D, Clare P
and Burnatowska-Hledin M: VACM-1, a cul-5 gene, inhibits cellular
growth by a mechanism that involves MAPK and p53 signaling
pathways. Am J Physiol Cell Physiol. 285:C1386–C1396. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bradley SE, Johnson AE, Le IP, Oosterhouse
E, Hledin MP, Marquez GA and Burnatowska-Hledin M: Phosphorylation
of VACM-1/Cul5 by protein kinase A regulates its neddylation and
antiproliferative effect. J Biol Chem. 285:4883–4895. 2010.
View Article : Google Scholar :
|
|
21
|
Zhang Y, Wang X, Wang Z, Tang H, Fan H and
Guo Q: miR-182 promotes cell growth and invasion by targeting
forkhead box F2 transcription factor in colorectal cancer. Oncol
Rep. 33:2592–2598. 2015.PubMed/NCBI
|
|
22
|
Li Y, Zhang D, Wang X, Yao X, Ye C, Zhang
S, Wang H, Chang C, Xia H, Wang YC, et al: Hypoxia-inducible
miR-182 enhances HIF1α signaling via targeting PHD2 and FIH1 in
prostate cancer. Sci Rep. 5:124952015. View Article : Google Scholar
|
|
23
|
Sun J, Ji J, Huo G, Song Q and Zhang X:
miR-182 induces cervical cancer cell apoptosis through inhibiting
the expression of DNMT3a. Int J Clin Exp Pathol. 8:4755–4763.
2015.PubMed/NCBI
|
|
24
|
Liu S, Howell PM and Riker AI:
Up-regulation of miR-182 expression after epigenetic modulation of
human melanoma cells. Ann Surg Oncol. 20:1745–1752. 2013.
View Article : Google Scholar
|
|
25
|
Zhou MJ, Chen FZ and Chen HC:
Ubiquitination-involved enzymes and cancer. Med Oncol. 31:932014.
View Article : Google Scholar
|
|
26
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
